| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 39 |
| 1 | PREDNISONE | 29 |
| 2 | CYCLOPHOSPHAMIDE | 26 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 26 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 26 |
| 5 | DOXORUBICIN | 20 |
| 6 | BENDAMUSTINE HCL | 17 |
| 7 | VINCRISTINE SULFATE | 11 |
| 8 | DOXORUBICIN HYDROCHLORIDE | 10 |
| 9 | GEMCITABINE HYDROCHLORIDE | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZANUBRUTINIB | 5 | 0.0011 |
| 1 | BENDAMUSTINE HCL | 17 | 0.0011 |
| 2 | BENDAMUSTINE HYDROCHLORIDE | 4 | 0.0005 |
| 3 | CARMUSTINE | 2 | 0.0004 |
| 4 | VINCRISTINE SULFATE | 11 | 0.0004 |
| 5 | DOXORUBICIN HYDROCHLORIDE | 10 | 0.0003 |
| 6 | CHLORAMBUCIL | 1 | 0.0003 |
| 7 | DOXORUBICIN | 20 | 0.0002 |
| 8 | RITUXIMAB-ABBS | 1 | 0.0002 |
| 9 | GEMCITABINE HYDROCHLORIDE | 10 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 40 |
| 1 | Corticosteroid [EPC] | 34 |
| 2 | Alkylating Drug [EPC] | 26 |
| 3 | Platinum-based Drug [EPC] | 13 |
| 4 | Kinase Inhibitor [EPC] | 6 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 4 |
| 6 | Topoisomerase Inhibitor [EPC] | 4 |
| 7 | Thalidomide Analog [EPC] | 3 |
| 8 | Xanthine Oxidase Inhibitor [EPC] | 3 |
| 9 | Azole Antifungal [EPC] | 2 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 40 | 0.0001 |
| 1 | Alkylating Drug [EPC] | 26 | 0.0001 |
| 2 | Topoisomerase Inhibitor [EPC] | 4 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 13 | 0.0000 |
| 4 | Corticosteroid [EPC] | 34 | 0.0000 |
| 5 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 1 | 0.0000 |
| 6 | Xanthine Oxidase Inhibitor [EPC] | 3 | 0.0000 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 4 | 0.0000 |
| 8 | Azole Antifungal [EPC] | 2 | 0.0000 |
| 9 | Kinase Inhibitor [EPC] | 6 | 0.0000 |